Hypoglycaemia in Type 2 Diabetes and in Elderly People

Hypoglycaemia in Clinical Diabetes, Second Edition

Volumn , Issue , 2007, Pages 239-264

  Zammitt, Nicola N ^a   Frier, Brian M ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

Glucagon like peptide 1 (GLP 1); Hypoglycaemia and insulin; Hypoglycaemia frequency; Hypoglycaemia in type 2 diabetes and elderly people; Hypoglycaemia pathophysiology

Indexed keywords

EID: 57749197121     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470516270.ch11     Document Type: Chapter

References (138)

1. Abraira C, Colwell JA, Nuttall FQ, Sawin CT, Nagel NJ, Comstock JP et al., the VA CSDM Group (1995). Veterans Affairs Cooperative Study on glycemic control and complications in Type II Diabetes (VA CSDM). Diabetes Care 18: 1113-23.
2. Ahren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A (2004). Inhibition of dipetidyl-peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 89: 2078-84.
3. Akram K, Pedersen-Bjergaard U, Borch-Johnsen K, Thorsteinsson B (2003). Recall of severe hypoglycaemic episodes and course of hypoglycaemia awareness in insulin treated type 2 diabetes in one year follow-up. Diabetologia 46 (Suppl 2) A304 (Abstract).
4. Akram K, Pedersen-Bjergaard U, Carstensen B, Borch-Johnsen K, Thorsteinsson B (2006). Frequency and risk factors of severe hypoglycaemia in insulin-treated type 2 diabetes: a cross-sectional survey. Diabetic Medicine 23: 750-6.
5. Allen KV, McAulay V, Sommerfield AJ, Frier BM (2004). Hypoglycaemia is uncommon with a combination of antidiabetic drugs and bedtime NPH insulin for type 2 diabetes. Practical Diabetes International 21: 179-82.
6. Amiel SA, Maran A, Powrie JK, Umpleby AM, Macdonald IA (1993). Gender differences in counterregulation to hypoglycaemia. Diabetologia 36: 460-4.
7. Anderson JH Jr, Brunelle RL, Keohane P, Koivisto VA, Trautmann ME, Vignati L, DiMarchi R (1997). Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. Archives of Internal Medicine 157: 1249-55.
8. Asplund K, Wilholm B-E, Lundman B (1991). Severe hypoglycaemia during treatment with glipizide. Diabetic Medicine 8: 726-31.
9. Avogaro A, Beltramello P, Gnudi L, Maran A, Valerio A, Miola M et al. (1993). Alcohol intake impairs glucose counterregulation during acute insulin-induced hypoglycemia in IDDM patients. Evidence for a critical role of free fatty acids. Diabetes 42: 1626-34.
10. Banarer S, McGregor V, Cryer PE (2002). Intraislet hyperinsulinemia prevents the glucagon response to hypoglycemia despite an intact autonomic response. Diabetes 51: 958-65.
11. Bastyr EJ, Huang Y, Brunelle RL, Vignati L, Cox DJ, Kotsamos JG (2000). Factors associated with nocturnal hypoglycemia among patients with type 2 diabetes new to insulin therapy. Diabetes Obesity and Metabolism 2: 39-46.
12. Ben-Ami H, Nagachandran P, Mendelson A, Edoute Y (1999). Drug-induced hypoglycemic coma in 102 diabetic patients. Arch Intern Med 159: 281-4.
13. Boden G, Soriano M, Hoeldtke RD, Owen OE (1983). Counterregulatory hormone release and glucose recovery after hypoglycemia in non-insulin-dependent patients. Diabetes 32: 231-7.
14. Bolli G, Tsalikian E, Haymond M, Cryer P, Gerich JE (1984). Defective glucose counterregulation after subcutaneous insulin in noninsulin dependent diabetes mellitus: paradoxical lack of compensatory increase in glucose production, roles of insulin resistance, abnormal neuroendocrine responses and islet paracrine interactions. Journal of Clinical Investigation 73: 1532-41.
15. Brierley EJ, Broughton DL, James OFW, Alberti KGMM (1995). Reduced awareness of hypoglycaemia in the elderly despite an intact counterregulatory response. Quarterly Journal of Medicine 88: 439-45.
16. Burge MR, Zeise T-M, Sobhy TA, Rassam AG, Schade DS (1999). Low-dose ethanol predisposes elderly fasted patients with type 2 diabetes to sulfonylurea-induced low blood glucose. Diabetes Care 22: 2037-43.
17. Campbell IW, Chalmers J, Herlihy OM (1994). Sulphonylurea-induced hypoglycaemia in elderly people with diabetes. Practical Diabetes 11: 102-3.
18. Chico A, Vidal-Rios P, Subira M, Novials A (2003). The continuous glucose monitoring system is useful for detecting unrecognised hypoglycemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control. Diabetes Care 26: 1153-7.
19. Chipkin SR, Klugh SA, Chasan-Taber L (2001). Exercise and diabetes. Cardiology Clinics 19: 489-505.
20. Cryer PE (1992). Iatrogenic hypoglycemia as a cause of hypoglycemia-associated autonomic failure in IDDM. A vicious cycle. Diabetes. 41: 255-60
21. Cryer PE (2002). Hypoglycaemia: The limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia 45: 937-48.
22. Cryer PE, Davis SN, Shamoon H (2003). Hypoglycemia in diabetes. Diabetes Care 26: 1902-12.
23. Cryer PE (2004). Diverse causes of hypoglycemia-associated autonomic failure in diabetes. New England Journal of Medicine 350: 2272-9.
24. Culy CR, Jarvis B (2001). Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus. Drugs 61: 1625-60.
25. Dailey G, Rosenstock J, Moses RG, Ways K (2004). Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care 27: 2363-8.
26. Davis SN, Goldstein RE, Jacobs J, Price L, Wolfe R, Cherrington AD (1993). The effects of differing insulin levels on the hormonal and metabolic response to equivalent hypoglycemia in normal humans. Diabetes 42: 263-72.
27. Davis SN, Fowler S, Costa F (2000). Hypoglycemic counterregulatory responses differ between men and women with type 1 diabetes. Diabetes 49: 56-72.
28. De Galan BE, Hoekstra JBL (2001). Glucose counterregulation in type 2 diabetes mellitus. Diabetic Medicine 18: 519-27.
29. Deary IJ, Hepburn DA, MacLeod KM, Frier BM (1993). Partitioning the symptoms of hypoglycaemia using multi-sample confirmatory factor analysis. Diabetologia 36: 771-7.
30. DeFronzo RA (1999). Pharmacologic therapy for type 2 diabetes mellitus. Annals of Internal Medicine 131: 281-303.
31. Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V et al. (2004a). One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24h glycemia and α-and β-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 53: 1187-94.
32. Degn KB, Brock B, Juhl CB, Djurhuus CB, Grubert J, Kim D et al. (2004b). Effect of intravenous infusion of exenatide (synthetic Exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 53: 2397-403.
33. Del Prato, Aragona M, Coppelli A (2002). Sulfonylureas and hypoglycaemia. Diabetes Nutrition and Metabolism 15: 444-51.
34. Desouza C, Salazar H, Cheong B, Murgo J, Fonseca V (2003). Association of hypoglycemia and cardiac ischemia. Diabetes Care 26: 1485-89.
35. Devlin JT, Hirshman M, Horton ED, Horton ES (1987). Enhanced peripheral and splanchnic insulin sensitivity in NIDDM men after single bout of exercise. Diabetes 36: 434-39.
36. Diamond MP, Hallerman L, Starick-Zych K, Jones TW, Connolly-Howard M, Tamborlane WV, Sherwin RS (1991). Suppression of counterregulatory hormone response to hypoglycemia by insulin per se. Journal of Clinical Endocrinology and Metabolism 72: 1388-90.
37. Donnelly LA, Morris AD, Frier BM, Ellis JD, Donnan PT, Durrant R et al., for the DARTS/MEMO collaboration (2005). Frequency and predictors of hypoglycaemia in type 1 and insulin-treated type 2 diabetes: a population based study. Diabetic Medicine 22: 449-55.
38. Fanelli C, Pampanelli S, Epifano L, Rambotti AM, Ciofetta M, Modarelli F et al. (1994). Relative roles of insulin and hypoglycaemia on induction of neuroendocrine responses to, symptoms of and deterioration of cognitive function in hypoglycaemia in male and female humans. Diabetologia 37: 797-807.
39. Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A et al. (2003). Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 26: 2370-7.
40. Fink RI, Revers RR, Kolterman OG, Olefsky JM (1985). The metabolic clearance of insulin and the feedback inhibition of insulin secretion are altered with ageing. Diabetes 34: 275-80.
41. Gold AE, MacLeod KM, Frier BM (1994). Frequency of severe hypoglycemia in patients with type 1 diabetes with impaired awareness of hypoglycemia. Diabetes Care 17: 697-703.
42. Goudswaard A, Furlong NJ, Rutten G, Stolk R, Valk G (2004). Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus (Cochrane review). Cochrane Database of Systematic Reviews 4: CD003418.
43. Haak T, Tiengo A, Draeger E, Suntum M, Waldhausl W (2005). Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obesity and Metabolism 7: 56-64.
44. Harrigan RA, Nathan MS, Beattie P (2001). Oral agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity and treatment. Annals of Emergency Medicine 38: 68-78.
45. Harrower A (2000). Gliclazide modified release: from once-daily administration to 24-hour blood glucose control. Metabolism 49 (Suppl 2): 7-11.
46. Hartling SG, Faber OK, Wegmann M-L, Wahlin-Boll E, Melander A (1987). Interaction of ethanol and glipizide in humans. Diabetes Care 10: 683-6.
47. Hay LC, Wilmhurst EG, Fulcher G (2003). Unrecognized hypo-and hyperglycemia in well-controlled patients with type 2 diabetes mellitus: the results of continuous glucose monitoring. Diabetes Technology and Therapeutics 5: 19-26.
48. Heller SR, Macdonald IA, Tattersall RB (1987). Counterregulation in type II (non-insulin-dependent) diabetes mellitus. Normal endocrine and glycaemic responses up to 10 years after diagnosis. Diabetologia 30: 924-9.
49. Henderson JN, Allen KV, Deary IJ, Frier BM (2003). Hypoglycaemia in insulin-treated type 2 diabetes: frequency, symptoms and impaired awareness. Diabetic Medicine 20: 1016-21.
50. Hepburn DA, MacLeod KM, Pell ACH, Scougal IJ, Frier BM (1993). Frequency and symptoms of hypoglycaemia experienced by patients with type 2 diabetes treated with insulin. Diabetic Medicine 10: 231-7.
51. Herman WH, Ilag LL, Johnson SL, Martin CL, Sinding J, AL Harthi A et al. (2005). A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care 28: 1568-73.
52. Hermansen K, Ronnemaa T, Petersen AH, Bellaire S, Adamson U (2004). Intensive therapy with inhaled insulin via the AERx insulin diabetes management system: a 12-week proof-of-concept trial in patients with type 2 diabetes. Diabetes Care 27: 162-7.
53. Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P, on behalf of the Levemir Treat-To-Target Group (2006). A 26-week, randomised, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetes Care 29: 1269-74.
54. Hollander PA, Blonde L, Rowe R, Mehta AE, Milburn JL, Hershon KS et al., for the Exubera Phase III Study Group (2004). Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes. Diabetes Care 27: 2356-62.
55. Holstein A, Plaschke A, Egberts E-H (2001). Lower incidence of severe hypoglycemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metabolism Research and Reviews 17: 467-73.
56. Israelian Z, Gosmanov NR, Szoke E, Schorr M, Bokhari S, Cryer PE et al. (2005). Increasing the decrement in insulin secretion improves glucagon responses to hypoglycemia in advanced type 2 diabetes. Diabetes Care 28: 2691-6.
57. Israelian Z, Szoke E, Woerle J, Bokhari S, Schorr M, Schwenke DC et al. (2006). Multiple defects in counterregulation of hypoglycemia in modestly advanced type 2 diabetes mellitus. Metabolism 55: 593-8.
58. Jaap AJ, Jones GC, McCrimmon RJ, Deary IJ, Frier BM (1998). Perceived symptoms of hypoglycaemia in elderly type 2 diabetic patients treated with insulin. Diabetic Medicine 15: 398-401.
59. Janka HU, Plewe G, Riddle MC, Klieb-Frisch C, Schweitzer MA, Yki-Järvinen H (2005). Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial therapy for type 2 diabetes. Diabetes Care 28: 254-9.
60. Jennings AM, Wilson RM, Ward JD (1989). Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents. Diabetes Care 12: 203-7.
61. Jonsson A, Chan JC, Rydberg T, Vaaler S, Hallengren B, Cockram CS et al. (2001). Pharmacodynamics and pharmacokinetics of intravenous glibenclamide in Caucasian and Chinese patients with type-2 diabetes. European Journal of Clinical Pharmacology 55: 721-7.
62. Kahn S, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP et al., on behalf of the ADOPT study group (2006). Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. New England Journal of Medicine 355: 2427-43.
63. Knop FK, Vilsbøll T, Larsen S, Madsbad S, Holst J, Krarup T (2003). No reactive hypoglycemia after subcutaneous administration of glucagon-like peptide-1 in lean type 2 diabetic patients and in patients with diabetes secondary to chronic pancreatitis. Diabetes Care 26: 2581-7.
64. Kobayashi K, Kimura M, Sakuguchi T, Hase A, Matsuoka A (1984). Pharmacokinetics of gliclazide in healthy and diabetic subjects. Journal of Pharmacological Science 73: 1684-7.
65. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bisack TA et al. (2003). Synthetic Exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 88: 3082-8.
66. Korzon-Burakowska A, Hopkins D, Matyka K, Lomas J, Pernet A, Macdonald I, Amiel S (1998). Effects of glycemic control on protective responses against hypoglycemia in type 2 diabetes. Diabetes Care 21: 283-90.
67. Landstedt-Hallin L, Adamson U, Lins P-E (1999). Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 84: 3140-5.
68. Larsen JJ, Dela F, Kjaer M, Galbo H (1997). The effect of moderate exercise on postprandial glucose homeostasis in NIDDM patients. Diabetologia 40: 447-53.
69. Lawrence PA, Cheely J (1980). Deterioration of diabetic patients' knowledge and management skills as determined during out-patient visits. Diabetes Care 3: 214-8.
70. Leese GP, Wang J, Broomhall J, Kelly P, Marsden A, MorrisonWet al., for the DARTS/MEMO Collaboration (2003). Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 26: 1176-80.
71. Levy CJ, Kinsley BT, Bajaj M, Simonson DC (1998). Effect of glycemic control on glucose counterregulation during hypoglycemia in NIDDM. Diabetes Care 21: 1330-8.
72. Liu D, Moberg E, Kollind M, Lins PE, Adamson U (1991a). A high concentration of circulating insulin suppresses the glucagon response to hypoglycemia in normal man. Journal of Clinical Endocrinology and Metabolism 73: 1123-8.
73. Liu DT, Adamson UC, Lins PE, Kollind ME, Moberg EA, Andreasson K (1991b). Inhibitory effect of circulating insulin on glucagon secretion during hypoglycemia in type I diabetic patients. Diabetes Care 15: 59-65.
74. MacLeod KM, Hepburn DA, Frier BM (1993). Frequency and morbidity of severe hypoglycaemia in insulin-treated diabetic patients. Diabetic Medicine 10: 238-45.
75. Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR, on behalf of the NN2211-1310 international study group (2004). Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting Glucagon-Like Peptide 1 analog Liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 27: 1335-42.
76. Maggs DG, Jacob R, Rife F, Caprio S, Tamborlane WV, Sherwin RS (1997). Counterregulation in peripheral tissues: effect of systemic hypoglycemia on levels of substrates and catecholamines in human skeletal muscle and adipose tissue. Diabetes 46: 70-6.
77. Marker JC, Cryer PE, Clutter WE (1992). Attenuated glucose recovery from hypoglycemia in the elderly. Diabetes 41: 671-8.
78. Matyka K, Evans M, Lomas J, Cranston I, Macdonald I, Amiel SA (1997). Altered hierarchy of protective responses against severe hypoglycemia in normal aging in healthy men. Diabetes Care 20: 135-41.
79. McAulay V, Deary IJ, Frier BM (2001). Symptoms of hypoglycaemia in people with diabetes. Diabetic Medicine 18: 690-705.
80. McAulay V, Frier BM (2001) Hypoglycaemia. In: Diabetes in Old Age. Second edition. Sinclair AJ, Finucane P, eds. John Wiley and Sons, Ltd, Chichester: 133-52.
81. McAulay V, Frier BM (2003). Insulin analogues and other developments in insulin therapy for diabetes. Expert Opinion in Pharmacotherapy 4: 1141-56.
82. Meier JJ, Nauck MA (2005). Glucagon-like peptide 1 (GLP-1) in biology and pathology. Diabetes Metabolism Research and Reviews 21: 91-117.
83. Meneilly GS, Cheung E, Tuokko H (1994a). Altered responses to hypoglycemia of healthy elderly people. Journal of Clinical Endocrinology and Metabolism 78: 1341-8.
84. Meneilly GS, Cheung E, Tuokko H (1994b). Counterregulatory hormone responses to hypoglycemia in the elderly patient with diabetes. Diabetes 43: 403-10.
85. Miller CD, Philips LS, Ziemer DC, Gallina DL, Cook CB, El-Kebbi IM (2001). Hypoglycemia in patients with type 2 diabetes mellitus. Archives of Internal Medicine 161: 1653-9.
86. Minaker KL, Rowe JW, Torino R, Pallotta JA (1982). Influence of age on clearance of insulin in man. Diabetes 31: 851-5.
87. Minuk HL, Vranic M, Marliss EB, Hanna AK, Albisser AM, Zinman B (1981). Glucoregulatory and metabolic response to exercise in obese noninsulin-dependent diabetes. American Journal of Endocrinology 240: E458-64.
88. Mitrakou A, Ryan C, Veneman T, Mokan M, Jenssen T, Kiss I et al. (1991). Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms and cerebral dysfunction. American Journal of Endocrinology 266: E67-74.
89. Murata GH, Hoffman RM, Shah JH, Wendel CS, Duckworth WC (2004). A probabilistic model for predicting hypoglycemia in type 2 diabetes mellitus. Archives of Internal Medicine 164: 1445-50.
90. Mutch WJ, Dingwall-Fordyce I (1985). Is it a hypo? Knowledge of the symptoms of hypoglycaemia in elderly diabetic patients. Diabetic Medicine 2: 54-6.
91. Nattrass M, Lauritzen T (2000). Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycemia in the treatment of type 2 diabetes? International Journal of Obesity and Metabolic Diseases 24 (Suppl 3): S21-31.
92. Nauck MA, Heimesaat MM, Behle K, Holst JJ, Nauck MS, Ritzel R et al. (2002). Effects of glucagonlike peptide 1 on counterregulatory hormone responses, cognitive functions and insulin secretion during hyperinsulinemic stepped hypoglycemic clamp experiments on healthy volunteers. Journal of Clinical Endocrinology and Metabolism 87: 1239-46.
93. Ortiz-Alonso FJ, Galecki A, Herman WH, Smith MJ, Jacquez JA, Halter JB (1994). Hypoglycemia counterregulation in elderly humans: relationship to glucose levels. American Journal of Endocrinology 267: E497-506.
94. Peacey SR, George E, Rostami-Hodjegan A, Bedford C, Harris N, Hardisty CA et al. (1996). Similar physiological and symptomatic responses to sulphonylurea and insulin induced hypoglycaemia in normal subjects. Diabetic Medicine 13: 634-41.
95. Pedersen-Bjergaard U, Pramming S, Thorsteinsson B (2003). Recall of severe hypoglycaemia and self-estimated state of awareness in type 1 diabetes. Diabetes Metabolism Research and Reviews 19: 232-40.
96. Pedersen-Bjergaard U, Pramming S, Heller SR, Wallace TM, Rasmussen AK, Jorgensen HV et al. (2004). Severe hypoglycaemia in 1076 adult patients with type 1 diabetes: influence of risk markers and selection. Diabetes Metabolism Research and Reviews 20: 479-86.
97. Pegg A, Fitzgerald D, Wise D, Singh BM, Wise PH (1991). A community-based study of diabetesrelated skills and knowledge in elderly people with insulin-requiring diabetes. Diabetic Medicine 8: 778-81.
98. Pramming S, Thorsteinsson B, Bendtson I, Binder C (1991). Symptomatic hypoglycaemia in 411 type 1 diabetic patients. Diabetic Medicine 8: 217-22.
99. Raskin P, Allen E, Hollander P, Gabbay RA, Hu P, Bode B, Garber A, for the INITIATE Study Group (2005). Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 26: 260-5.
100. Raslova K, Bogoev M, Raz I, Leth G, Gall MA, Hancu N (2004). Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Research and Clinical Practice 66: 193-201.
101. Rasmussen BM, Christiansen C, Rasmussen OW, Hansen C, Hermansen K (1999). Alcohol and postexercise metabolic responses in type 2 diabetes. Metabolism 48: 597-602.
102. Rasmussen BM, Orskov L, Schmitz O, Hermansen K (2001). Alcohol and glucose counterregulation during acute insulin-induced hypoglycemia in type 2 diabetic subjects. Metabolism 50: 451-7.
103. Reaven GM, Greenfield MS, Mondon CE, Rosenthal M, Wright D, Reaven EP (1982). Does insulin removal rate from plasma decline with age? Diabetes 31: 670-73.
104. Rendell M (2004). The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 64: 1339-58.
105. Riddle MC, Rosenstock J, Gerich J, on behalf of the insulin glargine 4002 study investigators (2003). Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26: 3080-6.
106. Rosenstock J, Schwartz SL, Clark CM, Park GD, Donley DW, Edwards MB (2001). Basal insulin therapy in type 2 diabetes. Diabetes Care 24: 631-6.
107. Rosenstock J, on behalf of the HOE 901/204 Study Investigators Group (2003). Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in type 2 diabetic patients. Diabetic Medicine 20: 545-51.
108. Rosenstock J, Hassman DR, Madder RD Brazinsky, Farrell J, Khutoryansky N, Hale PM: (2004). Repaglinide versus nateglinide monotherapy. Diabetes Care 27: 1265-70.
109. Ross SA, Zinman B, Campos RV, Strack T, Canadian Lispro Study Group (2001). A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents. Clinical Investigative Medicine 24: 292-8.
110. Sandoval DA, Ertl AC, Richardson MA, Tate DB, Davis SN (2003). Estrogen blunts neuroendocrine and metabolic responses to hypoglycemia. Diabetes 52: 1749-55.
111. Schernthaner G (2003). Gliclazide modified release: A critical review of pharmacodynamic, metabolic and vasoprotective effects. Metabolism 52 (Supplement 1): 29-34.
112. Schernthaner G, Grimaldi A, Di Mario U, Drzewoski J, Kempler P, Kvapil M et al. (2004a). GUIDE study: double blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. European Journal of Clinical Investigation 34: 535-42.
113. Schernthaner G, Kopp HP, Ristic S, Muzyka B, Peter L, Mitteregger G (2004b). Metabolic control in patients with type 2 diabetes using Humalog Mix50 injected three times daily: crossover comparison with human insulin 30/70. Hormone and Metabolic Research 36: 188-93.
114. Schwartz NS, Clutter WE, Shah SD, Cryer PE (1987). Glycemic thresholds for activation of glucose counterregulatory systems are higher than the thresholds for symptoms. Journal of Clinical Investigation 79: 777-81.
115. Segel SA, Paramore DA, Cryer PE (2002). Hypoglycemia-Associated Autonomic Failure in advanced type 2 diabetes. Diabetes 51: 724-33.
116. Seltzer HS (1989). Drug-induced hypoglycemia. Endocrinology and Metabolism Clinics of North America 18: 163-82.
117. Shamoon H, Friedman A, Canton C, Zacharowicz L, Hu M, Rossetti L (1994). Increased epinephrine and skeletal muscle responses to hypoglycemia in non-insulin-dependent diabetes mellitus. Journal of Clinical Investigation 93: 2562-71.
118. Shorr RI, Ray WA, Daugherty JR, Griffin MR (1997). Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Archives of Internal Medicine 157: 1681-6.
119. Spyer G, Hattersley A, Macdonald IA, Amiel S, MacLeod KM (2000). Hypoglycemic counterregulation at normal blood glucose concentrations in patients with well controlled type 2 diabetes. Lancet 356: 1970-4.
120. Stahl M, Berger W (1999). Higher incidence of severe hypoglycaemia leading to hospital admission in type 2 diabetic patients treated with long-acting versus short-acting sulphonylureas. Diabetic Medicine 16: 586-90.
121. Stephenson J, Fuller JH, on behalf of the EURODIAB IDDM Complications Study Group (1994). Microvascular and acute complications in IDDM patients: the EURODIAB IDDM complications study. Diabetologia 37: 278-85.
122. Strange P, Schwartz SL, Graf RJ, Polvino W, Weston I, Marbury TC et al. (1999). Pharmacokinetics, pharmacodynamics, and dose-response relationship of repaglinide in type 2 diabetes. Diabetes Technology and Therapeutics 1: 247-56.
123. Ter Braak EWMT, Appelman AMMF, van de Laak M, Stolk RP, van Haeften TW, Erkelens DW (2000). Clinical characteristics of type 1 diabetic patients with and without severe hypoglycemia. Diabetes Care 23: 1467-71.
124. Ter Braak EWMT, Appelman AMMF, van Der Tweel I, Erkelens DW, van Haeften TW (2002). The sulfonylurea glibenclamide induces impairment of glucagon and growth hormone responses during mild insulin-induced hypoglycemia. Diabetes Care 25: 107-12.
125. Tessier D, Dawson K, Tetrault JP, Bravo G, Meneilly GS (1994). Glibenclamide versus gliclazide in type 2 diabetes of the elderly. Diabetic Medicine 11: 974-80.
126. The Diabetes Control and Complications Trial Research Group (1993). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine 329: 977-86.
127. Thomson FJ, Masson EA, Leeming JT, Boulton AJM (1991). Lack of knowledge of symptoms of hypoglycaemia by elderly diabetic patients. Age and Ageing 20: 404-6.
128. Trovati M, Carta Q, Cavalot F, Vitali S, Banaudi C, Lucchina PG et al. (1984). Influence of physical training on blood glucose control, glucose tolerance, insulin secretion and insulin action in noninsulin-dependent diabetic patients. Diabetes Care 7: 416-20.
129. UK Hypoglycaemia Study Group (2007). Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 50: 1140-7.
130. UK Prospective Diabetes Study (UKPDS) Group (1998a). Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: 854-65.
131. UK Prospective Diabetes Study (UKPDS) Group (1998b). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837-52.
132. United Kingdom Prospective Diabetes Study Group (1998c). A 6 year randomised controlled trial comparing sulfonylurea, insulin and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy (UKPDS 24). Annals of Internal Medicine 128: 165-75.
133. Vilsbøll T, Krarup T, Madsbad S, Holst JJ (2001). No reactive hypoglycaemia in type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose. Diabetic Medicine 18: 144-9.
134. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R (2003). Insulin pump therapy. A meta-analysis. Diabetes Care 26: 1079-87.
135. Woerle HJ, Meyer C, Popa EM, Cryer PE, Gerich JE (2003). Renal compensation for impaired hepatic glucose release during hypoglycemia in type 2 diabetes. Further evidence for hepatorenal reciprocity. Diabetes 52: 1386-92.
136. Yki-Järvinen H, Dressler A, Ziemen M, the HOE 901/3002 study group (2000). Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 23: 1130-6.
137. Zammitt NN, Frier BM (2005). Hypoglycemia in type 2 diabetes: pathophysiology, frequency and effects of different treatment modalities. Diabetes Care 28: 2948-61.
138. Zander M, Madsbad S, Madsen JL, Holst JJ (2002). Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity and beta-cell function in type 2 diabetes: a parallel group study. Lancet 359: 824-30.